Helsinki, March 27, 2015

Shares of Novo Nordisk surged  over 10 percent after the pharma firm announced it was resubmitting a new insulin drug for clinical trials in the U.S.

Novo Nordisk yesterday announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month.

Novo Nordisk has a strong commitment to sustainability

The company believes that a healthy economy, environment and society is fundamental to long-term business success. This is why it manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursue business solutions that maximise value to its stakeholders as well as its shareholders.